AU2004293034B2 - EphA2 agonistic monoclonal antibodies and methods of use thereof - Google Patents
EphA2 agonistic monoclonal antibodies and methods of use thereof Download PDFInfo
- Publication number
- AU2004293034B2 AU2004293034B2 AU2004293034A AU2004293034A AU2004293034B2 AU 2004293034 B2 AU2004293034 B2 AU 2004293034B2 AU 2004293034 A AU2004293034 A AU 2004293034A AU 2004293034 A AU2004293034 A AU 2004293034A AU 2004293034 B2 AU2004293034 B2 AU 2004293034B2
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- epha2
- amino acid
- seq
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2012202569A AU2012202569A1 (en) | 2002-05-10 | 2012-05-02 | EPHA2 agonistic monoclonal antibodies and methods of use thereof |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60/379,368 | 2002-05-10 | ||
US60/418,204 | 2002-10-14 | ||
US60/460,358 | 2003-04-03 | ||
US52417703P | 2003-11-20 | 2003-11-20 | |
US60/524,177 | 2003-11-20 | ||
PCT/US2004/039112 WO2005051307A2 (en) | 2003-11-20 | 2004-11-19 | Epha2 agonistic monoclonal antibodies and methods of use thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003276832A Division AU2003276832A1 (en) | 2002-05-10 | 2003-05-12 | EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2012202569A Division AU2012202569A1 (en) | 2002-05-10 | 2012-05-02 | EPHA2 agonistic monoclonal antibodies and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2004293034A1 AU2004293034A1 (en) | 2005-06-09 |
AU2004293034B2 true AU2004293034B2 (en) | 2012-02-02 |
Family
ID=34632874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2004293034A Expired - Fee Related AU2004293034B2 (en) | 2002-05-10 | 2004-11-19 | EphA2 agonistic monoclonal antibodies and methods of use thereof |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1689346A4 (ja) |
JP (1) | JP4860477B2 (ja) |
KR (1) | KR20060135671A (ja) |
CN (1) | CN1905899B (ja) |
AU (1) | AU2004293034B2 (ja) |
CA (1) | CA2546763A1 (ja) |
WO (1) | WO2005051307A2 (ja) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6887674B1 (en) | 1998-04-13 | 2005-05-03 | California Institute Of Technology | Artery- and vein-specific proteins and uses therefor |
US6864227B1 (en) | 1998-04-13 | 2005-03-08 | California Institute Of Technology | Artery-and vein-specific proteins and uses therefor |
US7192698B1 (en) | 1999-08-17 | 2007-03-20 | Purdue Research Foundation | EphA2 as a diagnostic target for metastatic cancer |
US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
US7101976B1 (en) | 2000-09-12 | 2006-09-05 | Purdue Research Foundation | EphA2 monoclonal antibodies and methods of making and using same |
ATE530577T1 (de) * | 2002-05-10 | 2011-11-15 | Purdue Research Foundation | Epha2 agonistische monoklonale antikörper und deren anwendungsverfahren |
AU2003239585B2 (en) | 2002-05-23 | 2009-06-04 | Purdue Research Foundation | Low molecular weight protein tyrosine phosphatase (LMW-PTP) as diagnostic and therapeutic target |
US7381410B2 (en) | 2003-03-12 | 2008-06-03 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
JP2006521111A (ja) | 2003-03-12 | 2006-09-21 | バスジーン セラピューティクス, インコーポレイテッド | 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用 |
EP1730196B1 (en) | 2004-03-12 | 2010-12-22 | Vasgene Therapeutics, Inc. | Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth |
CN102746401A (zh) | 2004-03-12 | 2012-10-24 | 瓦斯基因治疗公司 | 结合ephb4、抑制血管发生和肿瘤生长的抗体 |
AU2005277567A1 (en) | 2004-08-16 | 2006-03-02 | Medimmune, Llc | Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity |
JP5219513B2 (ja) | 2004-09-23 | 2013-06-26 | バスジーン セラピューティクス,インコーポレイテッド | 血管形成及び腫瘍増殖阻害用ポリペプチド化合物 |
US8444973B2 (en) | 2005-02-15 | 2013-05-21 | Duke University | Anti-CD19 antibodies and uses in B cell disorders |
US20090220527A1 (en) * | 2005-12-21 | 2009-09-03 | Medlmmune, Llc | Affinity optimized epha2 agonistic antibodies and methods of use thereof |
US20100254996A1 (en) * | 2007-06-18 | 2010-10-07 | Medimmune, Llc | Synergistic treatment of cells that express epha2 and erbb2 |
AU2008287427B2 (en) | 2007-08-13 | 2014-10-09 | Vasgene Therapeutics, Inc. | Cancer treatment using humanized antibodies that bind to EphB4 |
MY150621A (en) * | 2007-08-30 | 2014-02-14 | Daiichi Sankyo Co Ltd | Anti-epha2 antibody |
WO2011109440A1 (en) | 2010-03-01 | 2011-09-09 | Caris Life Sciences Luxembourg Holdings | Biomarkers for theranostics |
US9469876B2 (en) | 2010-04-06 | 2016-10-18 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers for metastatic prostate cancer |
EP2595657A4 (en) * | 2010-07-22 | 2015-09-23 | Univ California | ANTITUMOR ANTIBODY ANTIBODIES AND METHODS OF USING SAME |
US9534044B2 (en) * | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
WO2016171242A1 (ja) * | 2015-04-24 | 2016-10-27 | 第一三共株式会社 | Epha2の検出 |
CN115025217B (zh) * | 2022-05-13 | 2023-05-05 | 广东齐美医药生物科技集团有限公司 | 干细胞裂解物联合活性多糖以及酪氨酸酶抑制剂在制备药物或化妆品中的用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001012172A1 (en) * | 1999-08-17 | 2001-02-22 | Purdue Research Foundation | Treatment of metastatic disease |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6927203B1 (en) * | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
ATE530577T1 (de) * | 2002-05-10 | 2011-11-15 | Purdue Research Foundation | Epha2 agonistische monoklonale antikörper und deren anwendungsverfahren |
ATE525398T1 (de) * | 2002-05-10 | 2011-10-15 | Medimmune Inc | Epha2 monoklonale antikörper und deren anwendungsverfahren |
WO2005056766A2 (en) * | 2003-12-04 | 2005-06-23 | Medimmune, Inc. | TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES |
-
2004
- 2004-11-19 KR KR1020067012152A patent/KR20060135671A/ko not_active Application Discontinuation
- 2004-11-19 CA CA002546763A patent/CA2546763A1/en not_active Abandoned
- 2004-11-19 AU AU2004293034A patent/AU2004293034B2/en not_active Expired - Fee Related
- 2004-11-19 JP JP2006541599A patent/JP4860477B2/ja not_active Expired - Fee Related
- 2004-11-19 CN CN2004800407205A patent/CN1905899B/zh not_active Expired - Fee Related
- 2004-11-19 WO PCT/US2004/039112 patent/WO2005051307A2/en active Application Filing
- 2004-11-19 EP EP04811773A patent/EP1689346A4/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001012172A1 (en) * | 1999-08-17 | 2001-02-22 | Purdue Research Foundation | Treatment of metastatic disease |
Also Published As
Publication number | Publication date |
---|---|
AU2004293034A1 (en) | 2005-06-09 |
EP1689346A4 (en) | 2007-11-21 |
JP2008500021A (ja) | 2008-01-10 |
CN1905899B (zh) | 2011-09-28 |
KR20060135671A (ko) | 2006-12-29 |
WO2005051307A3 (en) | 2006-09-08 |
CA2546763A1 (en) | 2005-06-09 |
EP1689346A2 (en) | 2006-08-16 |
CN1905899A (zh) | 2007-01-31 |
JP4860477B2 (ja) | 2012-01-25 |
WO2005051307A2 (en) | 2005-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1575509B1 (en) | Epha2 agonistic monoclonal antibodies and methods of use thereof | |
EP1519956B1 (en) | Epha2 monoclonal antibodies and methods of use thereof | |
AU2004293034B2 (en) | EphA2 agonistic monoclonal antibodies and methods of use thereof | |
US20100143345A1 (en) | Epha2 agonistic monoclonal antibodies and methods of use thereof | |
US7604799B2 (en) | EphA4 Antibodies | |
US20050153923A1 (en) | Targeted drug delivery using EphA2 or EphA4 binding moieties | |
US20090220527A1 (en) | Affinity optimized epha2 agonistic antibodies and methods of use thereof | |
AU2012202569A1 (en) | EPHA2 agonistic monoclonal antibodies and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PRIORITY DETAILS TO ADD DIVISIONAL PARENT 2003276832 12 MAY 2003 |
|
MK25 | Application lapsed reg. 22.2i(2) - failure to pay acceptance fee |